Spesolimab: First Approval

Spesolimab (spesolimab-sbzo; SPEVIGO(®)) is an interleukin (IL)-36 receptor antagonist being developed by Boehringer Ingelheim for the treatment of various immune-mediated disorders. In September 2022, spesolimab was approved in the USA for the treatment of generalized pustular psoriasis (GPP) flare...

Descripción completa

Detalles Bibliográficos
Autor principal: Blair, Hannah A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
AdisInsight Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744699/
https://www.ncbi.nlm.nih.gov/pubmed/36418672
http://dx.doi.org/10.1007/s40265-022-01801-4
_version_ 1784848978695684096
author Blair, Hannah A.
author_facet Blair, Hannah A.
author_sort Blair, Hannah A.
collection PubMed
description Spesolimab (spesolimab-sbzo; SPEVIGO(®)) is an interleukin (IL)-36 receptor antagonist being developed by Boehringer Ingelheim for the treatment of various immune-mediated disorders. In September 2022, spesolimab was approved in the USA for the treatment of generalized pustular psoriasis (GPP) flares in adults. This article summarizes the milestones in the development of spesolimab leading to this first approval for GPP flares. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40265-022-01801-4.
format Online
Article
Text
id pubmed-9744699
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-97446992022-12-14 Spesolimab: First Approval Blair, Hannah A. Drugs AdisInsight Report Spesolimab (spesolimab-sbzo; SPEVIGO(®)) is an interleukin (IL)-36 receptor antagonist being developed by Boehringer Ingelheim for the treatment of various immune-mediated disorders. In September 2022, spesolimab was approved in the USA for the treatment of generalized pustular psoriasis (GPP) flares in adults. This article summarizes the milestones in the development of spesolimab leading to this first approval for GPP flares. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40265-022-01801-4. Springer International Publishing 2022-11-23 2022 /pmc/articles/PMC9744699/ /pubmed/36418672 http://dx.doi.org/10.1007/s40265-022-01801-4 Text en © Springer Nature 2022, corrected publication 2022 https://creativecommons.org/licenses/by-nc/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle AdisInsight Report
Blair, Hannah A.
Spesolimab: First Approval
title Spesolimab: First Approval
title_full Spesolimab: First Approval
title_fullStr Spesolimab: First Approval
title_full_unstemmed Spesolimab: First Approval
title_short Spesolimab: First Approval
title_sort spesolimab: first approval
topic AdisInsight Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744699/
https://www.ncbi.nlm.nih.gov/pubmed/36418672
http://dx.doi.org/10.1007/s40265-022-01801-4
work_keys_str_mv AT blairhannaha spesolimabfirstapproval

Ejemplares similares